6,696 Shares in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Acquired by IRON Financial LLC

IRON Financial LLC bought a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 6,696 shares of the medical equipment provider's stock, valued at approximately $758,000.

A number of other hedge funds also recently bought and sold shares of the company. Dorsey & Whitney Trust CO LLC increased its stake in Zimmer Biomet by 2.3% in the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 4,594 shares of the medical equipment provider's stock worth $485,000 after purchasing an additional 102 shares during the period. M&T Bank Corp increased its stake in Zimmer Biomet by 0.4% in the 4th quarter. M&T Bank Corp now owns 26,827 shares of the medical equipment provider's stock worth $2,834,000 after purchasing an additional 108 shares during the period. MGO One Seven LLC increased its stake in Zimmer Biomet by 5.1% in the 4th quarter. MGO One Seven LLC now owns 2,254 shares of the medical equipment provider's stock worth $238,000 after purchasing an additional 110 shares during the period. Janney Montgomery Scott LLC increased its stake in Zimmer Biomet by 0.5% in the 1st quarter. Janney Montgomery Scott LLC now owns 25,647 shares of the medical equipment provider's stock worth $2,903,000 after purchasing an additional 118 shares during the period. Finally, FWG Holdings LLC increased its stake in Zimmer Biomet by 3.5% in the 4th quarter. FWG Holdings LLC now owns 3,715 shares of the medical equipment provider's stock worth $402,000 after purchasing an additional 124 shares during the period. Institutional investors own 88.89% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. Canaccord Genuity Group decreased their price target on Zimmer Biomet from $115.00 to $101.00 and set a "hold" rating on the stock in a research note on Monday, May 12th. Raymond James Financial decreased their price target on Zimmer Biomet from $119.00 to $104.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 6th. JMP Securities reduced their target price on Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating on the stock in a research note on Wednesday, May 7th. The Goldman Sachs Group reduced their target price on Zimmer Biomet from $120.00 to $104.00 and set a "neutral" rating on the stock in a research note on Tuesday, May 6th. Finally, Royal Bank Of Canada reduced their target price on Zimmer Biomet from $125.00 to $112.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 6th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $111.53.

Zimmer Biomet Price Performance

Shares of ZBH stock opened at $91.46 on Monday. The stock has a market cap of $18.10 billion, a price-to-earnings ratio of 20.23, a PEG ratio of 2.11 and a beta of 0.72. The business's fifty day moving average is $94.65 and its 200 day moving average is $102.20. Zimmer Biomet Holdings, Inc. has a twelve month low of $89.22 and a twelve month high of $116.71. The company has a quick ratio of 1.46, a current ratio of 2.44 and a debt-to-equity ratio of 0.53.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its earnings results on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, topping the consensus estimate of $1.77 by $0.04. Zimmer Biomet had a return on equity of 12.73% and a net margin of 11.86%. The business had revenue of $1.91 billion for the quarter, compared to the consensus estimate of $1.89 billion. During the same period in the previous year, the company posted $1.94 earnings per share. The company's revenue for the quarter was up 1.1% compared to the same quarter last year. Research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Thursday, June 26th will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 1.05%. The ex-dividend date is Thursday, June 26th. Zimmer Biomet's dividend payout ratio (DPR) is 21.24%.

Insiders Place Their Bets

In other Zimmer Biomet news, insider Sang Yi sold 1,000 shares of the business's stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total value of $95,000.00. Following the sale, the insider now directly owns 20,424 shares of the company's stock, valued at approximately $1,940,280. The trade was a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 1.39% of the company's stock.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.